LUCAR-G39P / Legend Biotech - LARVOL DELTA

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=11 | Terminated | Sponsor: The First Affiliated Hospital with Nanjing Medical University | N=33 ➔ 11 | Trial completion date: Jun 2028 ➔ Aug 2025 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2026 ➔ Jun 2025; Achieve the proof of concept.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=33 | Recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology